Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, ...
High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running ...
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Once a drug lost primary patent protection or hit a certain age, it was managed for steady — if declining — cash flow with ...
Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for ...
The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers ...
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check ...
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 ...
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can ...
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” ...
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results